Limb lengthening statistics 2026, measured from 192 verified clinics

The unit of measurement in these limb lengthening statistics is a clinic listing, not a surgery. A listing enters the directory when four things can be independently verified: at least one named surgeon with verifiable orthopaedic board certification or the regional equivalent, an active public practice confirmed through hospital affiliation or regulatory registration, evidence that the clinic performs limb lengthening rather than naming it among generic services, and a contactable business with at least 12 months of public presence. Each record is then confirmed against at least two sources that do not depend on each other. Clinics that fail are excluded.

Every number below is a count over those 192 listings as of 11 September 2026. Country counts are counts of listings. Method counts are counts of method mentions per listing, so a clinic that offers Ilizarov and PRECICE 2 appears under both. Price bands use only the 43 clinics that publish a figure or have a labelled patient or market figure attached; the other 149 were checked and publish nothing.

Three things the dataset cannot tell you. It cannot say how many operations happen, because clinics do not publish caseloads and no registry collects them. It cannot rank clinics by outcome, because outcome data is not published per clinic. And it cannot say what you will pay, because a published minimum is a starting quote, usually for a bilateral femur with the implant included and physiotherapy, hotel and hardware removal left out.

The United States hosts 64 of the 192 verified clinics, one in three. Turkey is second with 22, India third with 10. Those three countries hold exactly half the directory: 96 of 192. The seven EU and UK countries in the table (France 8, Germany 7, Poland 7, Spain 6, the United Kingdom 4, Italy 4, Greece 1) add up to 37 clinics, or 19.3%.

The long tail is long. Twenty of the 38 countries have two clinics or fewer: eight with two and twelve with one, listed in the table.

Read the US figure carefully. It counts hospital limb-reconstruction programs, Shriners Children's, Nemours, Boston Children's, CHOP and similar, that lengthen for congenital and post-traumatic deformity and do not publish a self-pay price. That is why 64 US listings produce only 6 published prices while 22 Turkish listings produce 10. Twenty of Turkey's 22 clinics are in Istanbul, the other two in Antalya, and nearly all are built around cosmetic stature lengthening. India's ten mix deformity and Ilizarov centres in Mumbai, Akola and Coimbatore with height-increase clinics in New Delhi and Gurgaon. Read limb lengthening by country as a map of where verified providers are, not of where the most surgeries happen.

Across the 192 clinics the directory records 368 method listings, 1.9 per clinic. Ilizarov external fixation leads with 99 listings (51.6% of clinics), the PRECICE 2 magnetic nail follows with 91 (47.4%), and LON, lengthening over a nail, has 61 (31.8%). The Taylor Spatial Frame appears 38 times (19.8%), Fitbone 23 (12.0%), LATN 15 (7.8%) and PRECICE Max 13 (6.8%).

Grouped by family: 141 listings are external frames (Ilizarov, TSF and its hexapod variants, Orthofix LRS, Salamehfix), 78 are hybrids that pair a frame with a nail (LON, LATN, quadrilateral LON, one combined system) and 149 are internal devices (the PRECICE family, Fitbone, Guichet, Albizzia, Betzbone, one growing prosthesis). Frames and internal devices are now offered in near-equal numbers.

Seven listings still name the PRECICE Stryde (5 as PRECICE Stryde, 2 as Stryde). The directory records the mention but does not treat Stryde as an available method: NuVasive Specialized Orthopedics recalled it in February 2021 (FDA recall Z-1323-2021, Class II, 2,360 units) after reports of pain and bony abnormalities where the telescoping nail segments meet.

The listing mix tracks the published literature with a lag. In Marwan's 2020 systematic review of 795 cosmetic-lengthening patients, 33.6% had a classic Ilizarov frame, 31.8% LON and 7.9% an implantable nail. Mittal's 2023 analysis of 2,563 US inpatient lengthenings (seven states, 2005–2015) found the share of internal femoral lengthening rising 10.2% per year from 2011 to 2015. Internal devices on 149 listings in 2026 is where that trend has led.

Only 43 of the 192 clinics (22.4%) publish a price or have a labelled patient or market figure on record; 149 were checked and publish nothing. Of the 43, 32 figures come from the clinic's own website, 4 from a labelled market benchmark, 4 from an estimate and 3 from patient reviews. Three US charity hospitals in the Shriners network, which publish a $0 patient price, are excluded from the bands.

The table shows the nine countries with at least two priced clinics. Figures are clinic-published minimum and maximum in US dollars, bilateral femur where the clinic states the segment. Median midpoint is the median, across that country's priced clinics, of each clinic's minimum and maximum averaged. It is the fairest single number for a country, not an average bill.

The spread is 9.6x between the US median midpoint ($137,625, 6 clinics) and India's ($14,400, 6 clinics), and 3.5x between the US and Turkey ($39,750, 10 clinics). Germany ($87,500, 3 clinics) and Poland ($68,350, 2 clinics) sit between. The $2,277 floor is a Moscow clinic's operation-only ruble price list converted to dollars; frame installation, removal and remounting are separate line items, so it is not a full-course price. The $313,000 ceiling is the Paley Institute's published package for two consecutive femur rounds, with hardware removal ($18,000–$28,000) billed separately. Seven more priced clinics sit in countries with a single priced listing (Canada, Colombia, the UAE, Greece, Egypt, Pakistan and Japan); they are in the dataset but not tabulated.

This table attributes each priced clinic's full published range to every method it lists. A clinic that offers Ilizarov, LON and PRECICE 2 at $20,000–$50,000 contributes that range to all three rows. So the rows measure what clinics offering a method publish, not the price of the device. The overlap is why the same $313,000 maximum appears under five methods: it is one Florida clinic that lists all five.

PRECICE Max carries the highest median midpoint, $97,000 across 9 priced clinics; four of those nine are in the US. PRECICE 2 sits at $69,817 (30 clinics). LON ($39,750, 28 clinics) and Ilizarov ($37,350, 22 clinics) are the methods whose priced clinics sit mostly outside the US: 18 of the 28 priced LON clinics are in Turkey, India or Russia, and only 2 of the 22 priced Ilizarov clinics are American. Their medians are 43% and 47% below PRECICE 2's. The motorised Fitbone nail lands at $46,600 (8 clinics), TSF at $40,574 (3 clinics). The three clinics still quoting a PRECICE Stryde price ($12,897–$120,000) are quoting for a device under recall, which is a reason to ask in writing which nail will be implanted.

The implant does not explain the spread. The same PRECICE 2 nail is priced from $12,897 to $313,000 across the 30 clinics that publish; the 24x range is the country, the hospital and what the package includes.

Every listing carries a research tier. Tier 1 (70 clinics, 36.5%) means surgeon credentials, hospital affiliation, regulatory status and published outcomes were cross-checked against independent sources. Tier 2 (87 clinics, 45.3%) means surgeon name, address and methods are verified but the outcome and regulatory review is not complete. Tier 3 (35 clinics, 18.2%) means limited public data was available at listing. A clinic cannot pay to change its tier.

The directory names 300 surgeons, and 284 of them (94.7%) have a biography drawn from a clinic, hospital or registry page rather than written in-house. 149 of the 192 clinics (77.6%) have a Google rating attached, pulled through the Places API from the listing linked on the profile; the median rating is 4.4 and the listings hold 103,198 reviews between them. Treat the review total with care: for a hospital-based program the Google listing is the hospital's, so its reviews cover every department, not limb lengthening.

21 listings (10.9%) record a Joint Commission International or US Joint Commission accreditation at hospital level. 102 clinics (53.1%) state an international-patient service. 60 (31.3%) have verified photographs on file. Consultation languages on record: English at 149 clinics, Spanish 41, Turkish 20, Arabic 18, Russian 17, German 15, French 12, Italian 10, Hindi 10, Japanese 5. In the re-verification tour that closed this snapshot, 184 clinics were re-checked, and all 192 carry a verification date inside the last 90 days.

Nobody publishes that number, so the question of how many limb lengthening surgeries per year take place has no sourced answer. No international registry exists, no national registry surfaced in the sources opened for this report, and none of them gives a worldwide count. Anyone quoting one is estimating.

What exists is partial. The largest counted series is Mittal and colleagues' 2023 study of the US Healthcare Cost and Utilisation Project database: 2,563 inpatient femoral and tibial lengthenings across seven states from 2005 to 2015, all indications. Only 56 of those patients (2.2%) carried a short-stature diagnosis, and 25.0% of that group self-paid, against 1.5% to 3.2% for congenital, post-traumatic and other diagnoses. The authors state the data cannot be generalised nationally or internationally.

The cosmetic literature is small. Marwan's 2020 systematic review pooled 795 patients from 11 studies published up to November 2019, with a mean gain of 6.7 cm. Giorgino's 2025 review pooled 760 patients from 12 studies to July 2024: 67% male, mean age 24.75, average gain 67 mm, satisfaction 88.8% to 98%. Both are decades of published cases, not annual volumes.

Single-centre numbers show the direction. Dror Paley told The New York Times in February 2026 that his West Palm Beach clinic did 155 cases in 2025, as reported in People's account of the piece. Shahab Mahboubian told NBC News in April 2023 he expected 50 stature-lengthening operations that year, up from 20 three years earlier. Novikov's Kurgan series, 131 cosmetic Ilizarov patients treated between 1983 and 2006, opens by stating that patients are increasingly undergoing the procedure.

The limb lengthening market figures in circulation, $4.1 billion in 2021 growing to $8.6 billion by 2030 at 8.7% a year, come from a market-research vendor's report (Spherical Insights) and were repeated by Euronews in September 2025. The report discloses no method and no procedure count; it is a modelled revenue estimate, not a statistic about surgeries.

Complication data has better denominators than volume data: 37% of Novikov's 131 patients had a complication, and 53% of the 257 patients in Frost's 2023 multicentre cohort of 314 FITBONE and PRECICE nails did.

This is the first edition. The directory ran a pass in June 2026, but these are the first counts produced under the current dataset rules, so there is no comparable earlier column to print. Comparison begins next quarter. The next snapshot will report the same limb lengthening statistics against the 11 September 2026 baseline: clinic count (192), country count (38), priced share (43 of 192), median midpoint by country and by method, tier distribution (70, 87, 35), rating coverage (149) and accreditation count (21).

What this pass changed is on record. Re-verification tour 1 re-checked 184 of the 192 clinics. Price rows were re-read from the clinic's own page and stamped with the read date; the Paley Institute's published packages, for example, now read femur $114,500, tibia $125,000 and $313,000 for two femur rounds, with hardware removal at $18,000–$28,000 billed separately. The PRECICE Stryde recall was corrected to its FDA classification, Class II, initiated 12 February 2021 and posted 30 March 2021, everywhere the site mentions it.

Expect the clinic count to move in both directions next quarter: additions in the twenty countries with one or two listings, removals where a practice stops advertising lengthening or fails a second-source check.

Cite the snapshot, not the page. Suggested form: Limb Lengthening Clinics Directory, 2026 report dataset: verified limb-lengthening clinics by country, method, tier and published price, snapshot 11 September 2026, limblengtheningclinics.com/blog/limb-lengthening-report-2026, data file /data/limb-lengthening-report-2026.json. The JSON carries every table on this page plus the language, photo and international-service counts, released for reuse with attribution under CC BY 4.0.

Quote numbers with their scope. 192 verified clinics in 38 countries is a count of listings that passed a two-source check on 11 September 2026, not a census of every provider. A median midpoint of $39,750 in Turkey is the median of ten clinics' published ranges, not the average bill, and it excludes removal, physiotherapy and travel unless the clinic says otherwise. Ilizarov 99 counts clinics that list the method, not operations performed with it. If a figure changes after the snapshot, the dataset file keeps its date and the change is logged under the corrections policy.

If you need a number this report does not contain, a global procedure count, a per-clinic outcome rate, a national average price, it is because no verifiable source publishes it. That absence is the most important of these limb lengthening statistics: the market can be measured by who advertises and what they publish, not by what happens in the operating room.